Cargando…
Disease Severity and Progression in Progressive Supranuclear Palsy and Multiple System Atrophy: Validation of the NNIPPS – PARKINSON PLUS SCALE
BACKGROUND: The Natural History and Neuroprotection in Parkinson Plus Syndromes (NNIPPS) study was a large phase III randomized placebo-controlled trial of riluzole in Progressive Supranuclear Palsy (PSP, n = 362) and Multiple System Atrophy (MSA, n = 398). To assess disease severity and progression...
Autores principales: | Payan, Christine A. M., Viallet, François, Landwehrmeyer, Bernhard G., Bonnet, Anne-Marie, Borg, Michel, Durif, Franck, Lacomblez, Lucette, Bloch, Frédéric, Verny, Marc, Fermanian, Jacques, Agid, Yves, Ludolph, Albert C., Leigh, Peter N., Bensimon, Gilbert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3150329/ https://www.ncbi.nlm.nih.gov/pubmed/21829612 http://dx.doi.org/10.1371/journal.pone.0022293 |
Ejemplares similares
-
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: The NNIPPS Study
por: Bensimon, Gilbert, et al.
Publicado: (2009) -
The Economic Costs of Progressive Supranuclear Palsy and Multiple System Atrophy in France, Germany and the United Kingdom
por: McCrone, Paul, et al.
Publicado: (2011) -
A new MRI rating scale for progressive supranuclear palsy and multiple system atrophy: validity and reliability
por: Rolland, Yan, et al.
Publicado: (2011) -
Advancing functional dysconnectivity and atrophy in progressive supranuclear palsy
por: Brown, Jesse A., et al.
Publicado: (2017) -
Plasma metabolite biomarkers for multiple system atrophy and progressive supranuclear palsy
por: Mori, Akio, et al.
Publicado: (2019)